Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Sep 1;25(17):5221-5230.
doi: 10.1158/1078-0432.CCR-18-3944. Epub 2019 Jun 25.

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

Affiliations
Clinical Trial

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

Robert L Ferris et al. Clin Cancer Res. .

Abstract

Purpose: Cetuximab, which modulates immune responses, may affect the efficacy of subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) who had experienced progression within 6 months of platinum-containing chemotherapy.

Patients and methods: In the randomized, open-label, phase III CheckMate 141 trial, patients were randomized 2:1 to nivolumab 3 mg/kg every 2 weeks or investigator's choice (IC) of single-agent chemotherapy, with stratification by prior cetuximab exposure. The primary endpoint was overall survival (OS); additional endpoints were progression-free survival, objective response rate, and safety.

Results: In patients with prior cetuximab exposure, the median OS was 7.1 months with nivolumab versus 5.1 months with IC (HR, 0.84; 95% CI, 0.62-1.15); OS benefit with nivolumab was maintained across most demographic subgroups. In patients without prior cetuximab exposure, the median OS was 8.2 months with nivolumab versus 4.9 months with IC (HR, 0.52; 95% CI, 0.35-0.77); OS benefit with nivolumab was maintained across patient baseline subgroups including tumor programmed death ligand 1 (PD-L1) expression (<1% or ≥1%). Grade 3-4 treatment-related adverse event rates favored nivolumab versus IC in both subgroups.

Conclusions: Nivolumab appeared to improve efficacy versus IC regardless of prior cetuximab use, supporting its use in patients with R/M SCCHN with or without prior cetuximab exposure. The reduction in risk of death with nivolumab compared with IC was greater in patients without prior cetuximab exposure versus with prior cetuximab exposure.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Immune activity mediated by cetuximab in the SCCHN tumor microenvironment. Binding of cetuximab to EGFR recruits CD8+ T cells, which are activated through MHC complex/TCR and B7/CTLA-4 binding. In responders to treatment, cetuximab-mediated activation of NK cells induces dendritic cell maturation via crosstalk to promote antigen presentation and lyse tumor cells through ADCC. However, cetuximab binding also recruits and expands the Treg population in the tumor microenvironment. These Treg cells inhibit cetuximab-mediated cytotoxicity via expression of immune checkpoint molecules such as PD-1, PD-L1, CTLA-4, and TIM-3. Upregulation of these immune checkpoint molecules is associated with the exhausted T-cell phenotype, as seen in nonresponders to cetuximab treatment. Immunosuppressive TGFβ is also expressed on Treg cells as well as accumulating MDSCs, leading to inhibition of cytolytic activity via reduced levels of granzyme B and perforin. ADCC, antibody-dependent cellular cytotoxicity; APC, antigen presenting cell; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; EGFR, epidermal growth factor receptor; MDSC, myeloid-derived suppressor cell; NK, natural killer; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1; SCCHN, squamous cell carcinoma of the head and neck; TCR, T-cell receptor; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; Treg, regulatory T cell.
Figure 2.
Figure 2.
A, OS in patients with prior cetuximab exposure; B, OS in patients without prior cetuximab exposure; C, Treatment effect on OS by baseline subgroups. NA, not available, minimum follow-up not reached; nivo, nivolumab.
Figure 3.
Figure 3.
Changes in the levels of circulating immune cell phenotypes in patients with and without prior cetuximab exposure in the nivolumab arm. A, CD8+ effector T cells. CD8+ effector T cells were defined as TCRα/β+CD8+CCR7CD45RA+. B, Regulatory T cells. Regulatory T cells were defined as CD4+CD25hiCD127loFoxP3+. Abbreviations: CR, complete response; IC, investigator's choice; PD, progressive disease; PR, partial response; SD, stable disease.
Figure 3.
Figure 3.
Changes in the levels of circulating immune cell phenotypes in patients with and without prior cetuximab exposure in the nivolumab arm. A, CD8+ effector T cells. CD8+ effector T cells were defined as TCRα/β+CD8+CCR7CD45RA+. B, Regulatory T cells. Regulatory T cells were defined as CD4+CD25hiCD127loFoxP3+. Abbreviations: CR, complete response; IC, investigator's choice; PD, progressive disease; PR, partial response; SD, stable disease.

References

    1. de Andrade DA, Machiels JP. Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy. Curr Opin Oncol 2012;24:211–7. - PubMed
    1. KEYTRUDA (pembrolizumab) for injection, for intravenous use [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc.; 2017.
    1. OPDIVO (nivolumab) injection, for intravenous use [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; 2017.
    1. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787–99. - PubMed
    1. Trivedi S, Concha-Benavente F, Srivastava RM, Jie HB, Gibson SP, Schmitt NC, et al. Immune biomarkers of anti-EGFR monoclonalantibodytherapy. Ann Oncol 2015;26:40–7. - PMC - PubMed

Publication types

MeSH terms